Nurix Therapeutics (NRIX) Change in Acquisitions & Divestments (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $119.6 million in Q2 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 16.0% year-over-year to $119.6 million in Q2 2026; TTM through May 2026 was $588.7 million, a 6.68% increase from a year earlier, with the FY2025 full-year figure at $617.5 million, up 34.39% from the prior year.
• Change in Acquisitions & Divestments for Q2 2026 stood at $119.6 million, down from $133.2 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for NRIX reached as high as $179.8 million in Q4 2025 and fell as low as $41.0 million in Q1 2023.
• Historically, Change in Acquisitions & Divestments has averaged $107.3 million across 5 years, with a median of $102.7 million in 2023.
• Across the five-year window, Change in Acquisitions & Divestments plunged 30.23% in 2023 and jumped 127.39% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $84.5 million in 2022, then dropped by 9.33% to $76.6 million in 2023, then soared by 108.21% to $159.5 million in 2024, then rose by 12.73% to $179.8 million in 2025, then tumbled by 33.51% to $119.6 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $119.6 million in Q2 2026, $133.2 million in Q1 2026, and $179.8 million in Q4 2025.